HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

BACKGROUND: Trastuzumab emtansine (T-DM1) is approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC), and has high efficacy. However, some patients exhibit primary resistance to T-DM1, and thus methods that can predict resista...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer
Main Authors: Sakai, Hitomi, Tsurutani, Junji, Iwasa, Tsutomu, Komoike, Yoshifumi, Sakai, Kazuko, Nishio, Kazuto, Nakagawa, Kazuhiko
Format: Artigo
Sprog:Inglês
Udgivet: Springer Japan 2018
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6132843/
https://ncbi.nlm.nih.gov/pubmed/29700710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-018-0861-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker